Clarity Completes Recruitment for Pivotal Prostate Cancer Imaging Trial
Closing price · 2026-10-27: $1.55 · -1.59%
Clarity Pharmaceuticals says its Phase III CLARIFY trial has dosed its planned target of participants, completing recruitment for the study of its prostate cancer imaging agent. Topline results are expected in the first half of 2027; the company says final results are intended to support a US regulatory application.